Treatment-resistant depression (TRD) is a leading cause of global long-term disability. COS’s CEO Stacie Hudgens has co-authored this newly published manuscript on the Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant https://link.springer.com/article/10.1007/s40263-022-00916-2#article-info

Clinical Outcomes Solutions (‘COS’), a global leader in the collection, analysis and reporting of patient-centred outcomes data with offices in Folkestone (UK), and Tucson and Chicago (USA), today marks five years of partnering collaboratively with FingerPost, a leading consultancy providing market-specific payer and Health Technology Assessment (HTA) insights and intelligence worldwide.    Established in 2013, COS is a global leader in …

ISOQOL 2021 took place in October, with online content available through end of November. Its theme – “Making valid decisions: Learning from Patient Reported Outcomes.” An intro to ISOQOL stated that “person-centred care is a fundamental shift in the delivery of health care that personalizes it by placing the patient/client at the nucleus of this care”.   At COS, we are committed to continuous, dedicated support …

June 14-20 is Men’s Health Week, and we are proud to be recognising the huge contributions our global team makes to the field of men’s health research. Our colleagues work tirelessly to further research, listening to the voices of those patients living with health issues that affect men disproportionately and ultimately allowing care pathways and treatments to be personalised, responsive, and …

It is a sad fact that cancer has – and likely will – touch all of our lives in some way. June 6 is global National Cancer Survivors Day. Our colleagues work tirelessly to further #oncology research, listening to the voices of those patients living with #cancer and ultimately allowing care pathways and treatments to be personalised, responsive, and effective.Here …

Our CEO, Stacie Hudgens, is co-author of a manuscript published by The Lancet on June 1: Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trialHepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The …

Adds complementary services in high growth sub-segment of HEOR Expands geographic presence with offices across the US and UK Validant, a leading global quality, compliance and regulatory consulting group, has acquired Clinical Outcomes Solutions (“COS”), a global leader in clinical outcomes assessments (COA). COS was founded in 2013 and has developed a leadership position in COA through its patient-centered approach …

12 May is Fibromyalgia awareness day, and we are proud to be recognising the huge contributions our global team makes to the field of patient research. Our colleagues recognise the need to further research, listen to the voices of those living with fibromyalgia and ultimately share knowledge on treatments. View relevant publications here:Li, Y., Morris, S., Cole, J., Dube, S., Smith, …

May is Skin Cancer Awareness Month, and we are proud to be recognising the huge contributions our global team makes to the field of oncology research. Our colleagues work tirelessly to further research, listening to the voices of those patients living with skin cancer and ultimately allowing care pathways and treatments to be personalised, responsive, and effective. View relevant publications here:Wali, G. …